Generic Firms Fear 'New Lifecycle Management Tool' From FDA Pill Size Guidance
This article was originally published in The Pink Sheet Daily
Final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.
You may also be interested in...
The US FDA revised two drug good manufacturing practice inspection programs in its compliance manual to reflect certain ICH guidance documents, efforts to control nitrosamine impurities and the use of inspection alternatives for evaluating facilities. Plus more recent developments in GMP and CMC compliance.
FDA denies ANDAs for one product because the generic tablet size is larger than the brand; the agency plans to release a draft guidance on generic equivalency to the reference listed drug in size, taste and smell.
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.